EUVIMEDEUVIMED entdecken
Kohortenstudie

Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study

Chitose Kawamura, Krishnan Bhaskaran, Takaaki Konishi, Yasuaki Sagara, Hiroko Bando, Tomohiro Shinozaki, Shuko Nojiri, Motohiko Adomi, Angel Y S Wong, Nanako Tamiya, Masao Iwagami

Breast Cancer · 2025

DOI: 10.1007/s12282-025-01769-5 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Breast Cancer, 2025. Verfasst von Chitose Kawamura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Breast Neoplasms, Cancer Survivors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Pfizer Health Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Breast cancer (BC) survivors may have an increased risk of endometrial cancer due to shared risk factors and tamoxifen use. However, the risk among women in Japan and that for each endocrine therapy regimen remains unknown when comparing BC survivors to women without BC. METHODS: We conducted a matched-cohort study using the JMDC claims database, covering company employees and their family members in Japan. Between January 2005 and December 2019, women aged 18-74 years with BC were matched to women without BC in a 1:4 ratio by age and database entry timing. Endometrial cancer risk was compared using stratified Cox regression. In addition, starting the follow-up at one year after matching, we assessed risk by endocrine treatment (tamoxifen, aromatase inhibitor [AI], and no endocrine therapy) using unstratified Cox regression. RESULTS: Among 23,729 BC survivors and 95,659 matched women (median age, 49.5 years), there were 56 vs 40 endometrial cancer cases (0.73 vs 0.13 cases/1,000 person-years, respectively), with adjusted hazard ratios of 7.71 (95% confidence interval 4.56-13.0). In the analysis by endocrine treatment, tamoxifen (n = 9,183; median 46.3 years), AI (n = 4,582; 58.1 years), and no endocrine therapy (n = 5,763; 49.4 years) cases were 26, 5, and 10 (0.92, 0.43, and 0.61 cases/1,000 person-years, respectively), and the adjusted hazard ratios were 5.67 (3.20-10.0), 2.17 (0.79-5.95), and 3.56 (1.66-7.65), respectively, compared to women without BC. CONCLUSIONS: BC survivors in Japan had an increased risk of endometrial cancer compared to women without BC. The risk was higher in women prescribed tamoxifen and those with no endocrine therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsBreast NeoplasmsCancer SurvivorsHumansFemaleMiddle AgedJapanAdultAgedTamoxifenRisk FactorsAntineoplastic Agents, HormonalAromatase InhibitorsYoung AdultCohort StudiesAdolescentCase-Control StudiesFollow-Up StudiesIncidence

Stichwörter der Autor:innen

Aromatase inhibitorBreast cancerCancer survivorEndometrial cancerTamoxifen

Substanzen

TamoxifenAntineoplastic Agents, HormonalAromatase Inhibitors

Autor:innen und Institutionen

  • Department of Health Services Research, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.
  • Department of Digital Health, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, Japan.
  • Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, University of Tsukuba, Ibaraki, Japan.
  • Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
  • Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Förderung

  • Pfizer Health Research Foundation

Zitieren

APA

Kawamura, C., Bhaskaran, K., Konishi, T., Sagara, Y., Bando, H., Shinozaki, T., Nojiri, S., Adomi, M., Wong, A. Y. S., Tamiya, N., & Iwagami, M. (2025). Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study. Breast Cancer. https://doi.org/10.1007/s12282-025-01769-5

Vancouver

Kawamura C, Bhaskaran K, Konishi T, Sagara Y, Bando H, Shinozaki T, et al. Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study. Breast Cancer. 2025. doi:10.1007/s12282-025-01769-5

BibTeX
@article{Kawamura2025,
  author = {Kawamura, Chitose and Bhaskaran, Krishnan and Konishi, Takaaki and Sagara, Yasuaki and Bando, Hiroko and Shinozaki, Tomohiro and Nojiri, Shuko and Adomi, Motohiko and Wong, Angel Y S and Tamiya, Nanako and Iwagami, Masao},
  title = {Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-025-01769-5}
}
Kostenlos starten →